June 28, 2021 -- ImmunityBio and NantOmics are sharing a new approach they have developed for identifying and validating neoepitope and neoepitope-reactive T cells for the development of personalized and precision medicines.
Neoepitopes are short peptide sequences that mutate in tumors and can generate an immune response. A description of the approach was published in the June issue of the Journal for Immunotherapy of Cancer.
The approach combines the two firms' bioinformatics expertise in order to predict neoepitopes based on genomic and expression analyses that will likely prompt an immune response, and is used with ImmunityBio's Adeno platform, they said.
The method can help identify tumor-specific immunogenic targets for individualized treatment including chimeric antigen receptor T-cell therapies and vaccines. Efficacy of these therapies could be further enhanced by combining them with an immune enhancer such as ImmunityBio's Anktiva or natural killer cells.
The technology was developed in collaboration with researchers at the Friedrich Alexander University in Erlangen, Germany, and the U.S. National Cancer Institute in Bethesda, MD.
Copyright © 2021 scienceboard.net